INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Paper

Recent Advances in Stability-Indicating Chromatographic Methods for Simultaneous Quantitative Analysis of Combination Drug Products: Principles, Method Development Strategies, Validation, And Regulatory Perspectives

Ajinkya Gulhane*, Dr. Neelima Naneriya

Department of Pharmacy, Oriental University, Indore (M.P)-453555.

ARTICLE INFO

Published: 05 Aug 2026
Keywords:
Stability-indicating analytical methods, Chromatographic method development, RP-HPLC, UHPLC, UPLC, LC–MS/MS, Analytical Quality by Design (AQbD).
DOI:
10.5281/zenodo.21802665

ABSTRACT

The increasing use of fixed-dose combination (FDC) pharmaceutical products has created a growing demand for robust, sensitive, and stability-indicating analytical methods capable of simultaneously quantifying multiple active pharmaceutical ingredients (APIs) in the presence of impurities and degradation products. Chromatographic techniques, particularly reversed-phase high-performance liquid chromatography (RP-HPLC), ultra-high-performance liquid chromatography (UHPLC), ultra-performance liquid chromatography (UPLC), high-performance thin-layer chromatography (HPTLC), and liquid chromatography–mass spectrometry (LC–MS/MS), have become indispensable tools for pharmaceutical quality control and regulatory compliance. This review provides a comprehensive overview of recent advances in stability-indicating chromatographic methods for the simultaneous quantitative analysis of combination drug products. The principles of chromatographic method development, including selection of stationary phase, mobile phase optimization, gradient elution, and detector selection, are critically discussed. The review further highlights the integration of Analytical Quality by Design (AQbD) concepts, including Analytical Target Profile (ATP), Critical Quality Attributes (CQAs), Critical Method Parameters (CMPs), risk assessment, Design of Experiments (DoE), Response Surface Methodology (RSM), and lifecycle management for systematic analytical procedure development. Comprehensive coverage is provided on forced degradation studies, separation of degradation products, impurity profiling, method validation according to ICH Q2(R2), and current regulatory expectations under ICH Q1, Q3A, Q3B, Q14, USP, FDA, EMA, WHO, and ISO guidelines. Recent technological innovations such as core-shell and monolithic columns, nano-liquid

***Corresponding Author:** Ajinkya Gulhane
Address: *Research Scholar, Department of Pharmacy, Oriental University, Indore (M.P)-453555.*
Email ✉: ajinkyagulhane1@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

chromatography, microfluidic platforms, artificial intelligence, machine learning, chemometrics, process analytical technology (PAT), digital chromatography, laboratory automation, robotics, and green analytical chemistry are also discussed. The review emphasizes the transition from conventional analytical approaches to intelligent, risk-based, and sustainable chromatographic platforms that support pharmaceutical quality, regulatory compliance, and continuous lifecycle management. Collectively, this review serves as an updated scientific resource for researchers, analysts, and regulatory professionals involved in the development and application of stability-indicating chromatographic methods for combination drug products.

INTRODUCTION

Pharmaceutical analysis plays a vital role in ensuring the quality, safety, efficacy, and consistency of drug products throughout their lifecycle. It supports drug discovery, formulation development, quality control, stability testing, and regulatory approval. Among the available analytical techniques, chromatographic methods are widely employed because of their high sensitivity, selectivity, accuracy, and ability to separate active pharmaceutical ingredients (APIs), impurities, and degradation products in complex formulations.

The increasing use of fixed-dose combination (FDC) products, which contain two or more APIs in a single dosage form, has created a growing need for simultaneous analytical methods. These methods reduce analysis time, solvent consumption, and operational costs while enabling accurate quantification of multiple drugs in a single run. However, differences in the physicochemical properties and degradation behavior of individual APIs make method development more challenging.

Drug stability is a critical quality attribute that determines the ability of a pharmaceutical product to maintain its identity, potency, purity, and safety during storage. Environmental factors such as heat, light, humidity, oxidation, and pH can cause chemical degradation, leading to the formation of degradation products that may reduce therapeutic efficacy or pose safety concerns. Therefore, stability-indicating chromatographic methods are essential for separating APIs from their degradation products and impurities during stability studies.

Regulatory agencies, including the International Council for Harmonisation (ICH), the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the United States Pharmacopeia (USP), require validated stability-indicating methods for pharmaceutical quality assessment. Recent guidelines such as ICH Q14 and ICH Q2(R2) emphasize a science- and risk-based approach to analytical procedure development, validation, and lifecycle management.

Advances in chromatographic technologies, including HPLC, UHPLC, UPLC, HPTLC, and LC–MS/MS, have significantly improved analytical performance by offering higher resolution, shorter analysis times, greater sensitivity, and reduced solvent consumption. Furthermore, the integration of Analytical Quality by Design (AQbD), chemometrics, artificial intelligence, and green analytical chemistry has transformed modern method development into a more systematic, efficient, and sustainable process.

Combination Drug Products

Combination drug products, commonly known as fixed-dose combination (FDC) products, are pharmaceutical formulations that contain two or more active pharmaceutical ingredients (APIs) in a single dosage form at predetermined doses. These formulations are developed to improve therapeutic outcomes by targeting multiple disease pathways simultaneously while simplifying treatment regimens. Combination products are widely used in the management of chronic

diseases such as hypertension, diabetes mellitus, cardiovascular disorders, tuberculosis, HIV/AIDS, and cancer. The increasing development of FDCs has also created a growing demand for robust stability-indicating analytical methods capable of simultaneously quantifying multiple APIs and their degradation products.

Advantages of Combination Drug Products

Combination drug products offer several clinical and pharmaceutical advantages over single-drug formulations. By incorporating multiple APIs into one dosage form, they simplify medication regimens, reduce dosing frequency, and improve patient adherence to long-term therapy. FDCs may also produce synergistic or complementary pharmacological effects, resulting in enhanced therapeutic efficacy while minimizing the risk of drug resistance in diseases such as tuberculosis and HIV. Furthermore, combination products can reduce manufacturing, packaging, transportation, and healthcare costs, making treatment more economical for both patients and healthcare systems.

Table 1. Advantages of Combination Drug Products

Advantage	Description
Improved patient compliance	Simplifies treatment regimen and enhances adherence.
Reduced pill burden	Decreases the number of tablets or capsules taken daily.
Synergistic therapeutic action	Combines complementary mechanisms of action to improve efficacy.
Cost effectiveness	Reduces manufacturing, packaging, and treatment costs.
Better disease management	Improves therapeutic outcomes in chronic diseases.

Challenges in the Analysis of Combination Drug Products

Despite their therapeutic benefits, combination drug products present significant analytical challenges during method development and validation. APIs within the same formulation often differ in their physicochemical properties, including polarity, solubility, pKa, and UV absorption characteristics, making simultaneous chromatographic separation difficult. Additionally, each drug may undergo distinct degradation pathways under stress conditions, resulting in multiple degradation products that must be effectively resolved. Peak overlap between APIs, impurities, and degradation products can compromise analytical accuracy, while formulation excipients may interfere with chromatographic detection and quantification. Consequently, the development of selective, robust, and stability-indicating chromatographic methods is essential for ensuring accurate quality assessment of combination drug products.

Table 2. Major Analytical Challenges in Combination Drug Products

Challenge	Impact on Chromatographic Analysis
Different physicochemical properties	Difficult optimization of chromatographic conditions due to differences in polarity, solubility, and pKa.
Different degradation pathways	Formation of multiple degradation products requiring effective separation.
Peak overlap	Co-elution of APIs, impurities, or degradation products, reducing method specificity.
Excipient interference	Matrix components may interfere with peak detection, resolution, or quantification.

Drug Stability

Drug stability is a critical quality attribute that ensures a pharmaceutical product maintains its identity, strength, quality, purity, and therapeutic efficacy throughout its storage period. Stability evaluation is an essential component of pharmaceutical development because it determines the appropriate storage conditions, packaging requirements, and shelf life of a drug product. Regulatory agencies require comprehensive stability studies to ensure that medicines remain safe and effective until their expiration date.

Stability Studies

Stability studies are systematic investigations conducted to evaluate the effect of environmental factors such as temperature, humidity, light, and oxidation on the quality of pharmaceutical products. These studies help establish the product's shelf life, recommended storage conditions, packaging system, and expiration date. According to ICH guidelines, stability studies include long-term, intermediate, accelerated, and stress (forced degradation) testing to assess the degradation behavior of drug substances and formulations.

Shelf Life

Shelf life is the period during which a pharmaceutical product is expected to remain within its approved quality specifications when stored under recommended conditions. It is determined using stability study data and represents the time during which the product maintains acceptable potency, purity, and safety. Once the shelf life expires, the product may undergo significant degradation, reducing its therapeutic effectiveness or generating potentially harmful degradation products.

Degradation Mechanisms

Drug degradation is the chemical or physical breakdown of pharmaceutical compounds caused by environmental or formulation-related factors. Understanding degradation mechanisms is essential for developing stability-indicating chromatographic methods capable of separating APIs from their degradation products.

(A) Hydrolysis

Hydrolysis is one of the most common degradation pathways, occurring when drug molecules react with water under acidic, alkaline, or neutral conditions. Functional groups such as esters, amides, lactams, and carbamates are particularly susceptible to hydrolysis, leading to reduced drug potency and the formation of degradation products.

Drug (Ester/Amide) + H_2O

↓

Acid/Base Catalysis

↓

Alcohol + Carboxylic Acid (or Amine)

(B) Oxidation

Oxidation involves the reaction of drug molecules with oxygen or oxidizing agents such as hydrogen peroxide. Drugs containing phenolic, amine, sulfide, or unsaturated functional groups are particularly prone to oxidative degradation. Oxidation may result in discoloration, potency loss, or formation of toxic impurities.

Drug + O_2 / H_2O_2

↓

Oxidation

↓

Oxidized degradation products

(C) Photolysis

Photolytic degradation occurs when pharmaceutical compounds are exposed to ultraviolet (UV) or visible light. Light energy

induces molecular excitation, leading to bond cleavage, oxidation, isomerization, or rearrangement reactions. Photosensitive drugs therefore require protective packaging such as amber-colored containers.

Drug + UV / Visible Light
↓
Molecular Excitation
↓
Photodegradation Products

(D) Thermal Degradation

Thermal degradation results from exposure to elevated temperatures during manufacturing, transportation, or storage. Heat accelerates chemical reactions such as hydrolysis, oxidation, decarboxylation, and molecular rearrangements, thereby reducing drug stability.

Drug + Heat
↓
Chemical Decomposition
↓
Degradation Products

(E) Humidity-Induced Degradation

Moisture can significantly affect pharmaceutical stability by promoting hydrolysis, altering crystalline structure, and facilitating microbial growth in susceptible formulations. Hygroscopic drugs readily absorb atmospheric moisture, resulting in reduced stability and altered physicochemical properties.

Drug + Moisture
↓
Water Absorption
↓
Hydrolysis / Physical Changes

(F) Effect of pH

The stability of many pharmaceutical compounds is highly dependent on pH. Acidic or alkaline conditions can accelerate degradation reactions, particularly hydrolysis. Determining the optimum pH is therefore an important step in formulation development and chromatographic method optimization.

Table 3. Major Drug Degradation Mechanisms

Degradation Mechanism	Causative Factor	Commonly Affected Functional Groups	Effect on Drug
Hydrolysis	Water, acidic or alkaline conditions	Esters, amides, lactams	Loss of potency and formation of hydrolytic products
Oxidation	Oxygen, hydrogen peroxide, free radicals	Phenols, amines, sulfides	Oxidized impurities and discoloration
Photolysis	UV and visible light	Aromatic and conjugated compounds	Structural modification and potency loss
Thermal degradation	Elevated temperature	Heat-sensitive compounds	Chemical decomposition
Humidity	Moisture and water vapor	Hygroscopic drugs	Hydrolysis and physical instability
pH effects	Acidic or alkaline environment	pH-sensitive drugs	Accelerated degradation and reduced stability

STABILITY-INDICATING ANALYTICAL METHODS

Stability-indicating analytical methods (SIAMs) are essential tools in pharmaceutical analysis for evaluating the stability of drug substances and drug products. These methods are

specifically designed to accurately quantify the active pharmaceutical ingredient (API) while effectively separating it from degradation products, process-related impurities, and formulation excipients. Consequently, SIAMs play a crucial role in stability studies, quality control, formulation development, and regulatory submissions.

A stability-indicating analytical method (SIAM) is a validated analytical procedure that accurately and specifically measures the active pharmaceutical ingredient without interference from degradation products, impurities, excipients, or other potential contaminants. These methods are commonly developed using chromatographic techniques such as RP-HPLC, UHPLC, UPLC, and LC–MS/MS due to their high selectivity and resolution.

Characteristics of Stability-Indicating Methods

An ideal stability-indicating analytical method should possess high specificity, sensitivity, accuracy, precision, and robustness. It should effectively resolve the API from all degradation products formed during forced degradation studies and demonstrate acceptable system suitability parameters. Furthermore, the method should be reproducible, capable of detecting low levels of impurities, and suitable for routine quality control as well as regulatory compliance.

Table 4. Characteristics of an Ideal Stability-Indicating Method

Characteristic	Significance
Specificity	Separates API from impurities, excipients, and degradation products.
Accuracy	Provides results close to the true value.
Precision	Produces consistent and reproducible results.
Sensitivity	Detects low concentrations of analytes and impurities.
Robustness	Maintains performance despite small changes in analytical conditions.
Resolution	Achieves complete separation of closely eluting peaks.
Linearity	Demonstrates proportional response over the desired concentration range.

Importance of Stability-Indicating Methods

Stability-indicating methods are indispensable throughout the pharmaceutical product lifecycle. They are used to monitor drug stability during storage, identify degradation pathways, quantify degradation products, establish shelf life, and ensure compliance with regulatory requirements. These methods also support formulation development, process optimization, impurity profiling, and quality assurance by providing reliable and reproducible analytical data.

Difference Between Assay Method, Stability-Indicating Assay, and Impurity Profiling

Although assay methods, stability-indicating assays, and impurity profiling are all used in pharmaceutical analysis, they differ in their objectives and analytical capabilities. Conventional assay methods determine only the content of the active ingredient, whereas stability-indicating assays specifically quantify the API in the presence of degradation products and impurities. In contrast, impurity profiling focuses on the identification, separation, quantification, and characterization of process-related impurities and degradation products to ensure product safety and regulatory compliance.

Table 5. Comparison of Analytical Methods

Parameter	Assay Method	Stability-Indicating Assay	Impurity Profiling
Primary objective	Quantification of API	Quantification of API in the presence of degradation products	Identification and quantification of impurities and degradation products
Degradation product separation	Not essential	Essential	Essential
Specificity	Moderate	High	Very high
Forced degradation studies	Not required	Required	Required
Stability evaluation	No	Yes	Yes
Regulatory application	Routine quality control	Stability studies and product release	Impurity control and regulatory submissions
Typical analytical techniques	UV Spectrophotometry, HPLC	RP-HPLC, UHPLC, UPLC, LC–MS/MS	HPLC, UPLC, LC–MS/MS, HRMS

CHROMATOGRAPHIC TECHNIQUES USED IN STABILITY-INDICATING ANALYSIS

Chromatographic techniques are the cornerstone of pharmaceutical analysis due to their high selectivity, sensitivity, and ability to simultaneously separate active pharmaceutical ingredients (APIs), impurities, excipients, and degradation products. Advances in stationary phases, detector technologies, and chromatographic instrumentation have significantly improved the efficiency, speed, and reliability of stability-indicating analytical methods. The choice of chromatographic technique depends on the physicochemical properties of analytes, analytical objectives, sensitivity requirements, and regulatory expectations.

Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC)

Principle

RP-HPLC separates analytes based on differences in hydrophobic interactions between a non-polar stationary phase (typically C18 or C8 columns) and a relatively polar mobile phase. Compounds with greater hydrophobicity generally exhibit longer retention times.

Instrumentation

A typical RP-HPLC system consists of a solvent reservoir, degasser, high-pressure pump, injector, chromatographic column, detector (UV/PDA/DAD), and data acquisition software.

Advantages

RP-HPLC offers excellent resolution, high precision, reproducibility, wide applicability, and compatibility with a broad range of pharmaceutical compounds. It remains the most widely accepted technique for routine quality control and stability studies.

Applications

- Simultaneous estimation of combination drug products
- Stability-indicating assays
- Impurity profiling
- Dissolution testing
- Assay of pharmaceutical formulations

Recent Advances

Recent developments include core-shell columns, AQbD-based method development, automated method optimization, chemometric tools, and hyphenated techniques such as LC–MS for enhanced analytical performance.

Ultra-High Performance Liquid Chromatography (UHPLC)

UHPLC employs sub-2 µm particle columns and higher operating pressures than conventional HPLC, resulting in improved separation efficiency, enhanced sensitivity, and significantly shorter analysis times. UHPLC is particularly useful for high-throughput pharmaceutical laboratories requiring rapid stability studies, impurity analysis, and simultaneous determination of multiple APIs while reducing solvent consumption.

Ultra-Performance Liquid Chromatography (UPLC)

UPLC utilizes very small particle-size columns (typically <2 µm) combined with ultra-high operating pressures to achieve superior chromatographic efficiency. Compared with conventional HPLC, UPLC provides faster analysis, improved peak resolution, reduced mobile-phase consumption, and lower sample requirements. These characteristics support the principles of green analytical chemistry by minimizing solvent usage, waste generation, and overall environmental impact.

High-Performance Thin-Layer Chromatography (HPTLC)

HPTLC is an advanced planar chromatographic technique that enables simultaneous analysis of multiple samples with relatively low operational cost. It is widely used for pharmaceutical quality control, herbal drug standardization, and preliminary stability evaluation.

Advantages

- Simple and cost-effective
- High sample throughput
- Minimal solvent consumption
- Simultaneous analysis of several samples

Limitations

- Lower sensitivity than HPLC
- Limited quantitative accuracy for trace-level analysis
- Lower resolution for highly complex mixtures

Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS)

LC–MS/MS combines chromatographic separation with mass spectrometric detection, providing exceptional sensitivity and structural information. It is considered one of the most powerful techniques for identifying degradation products, impurity profiling, metabolite analysis, and structural elucidation. LC–MS/MS has become an indispensable tool during forced degradation studies and regulatory investigations where unknown degradation products must be characterized.

High-Performance Liquid Chromatography with Diode Array Detection (HPLC–DAD)

HPLC–DAD combines conventional HPLC separation with diode array detection, allowing simultaneous acquisition of UV spectra across multiple wavelengths. This technique is particularly valuable for assessing peak purity, detecting co-eluting compounds, and confirming chromatographic specificity during stability-indicating method development. HPLC–DAD also facilitates selection of optimum detection

wavelengths for simultaneous estimation of combination drug products.

Ion-Pair Chromatography

Ion-pair chromatography is a modified reversed-phase technique used for the separation of highly polar or ionizable compounds. The addition of ion-pairing reagents to the mobile phase enhances retention and improves resolution of ionic analytes that are difficult to separate by conventional RP-HPLC. This technique is particularly useful for amino acids, peptides, quaternary ammonium compounds, and highly polar pharmaceutical substances.

Chiral Chromatography

Chiral chromatography is employed to separate optical isomers (enantiomers) using chiral stationary phases or chiral mobile-phase additives. Since different enantiomers may exhibit distinct pharmacological activity, toxicity, and metabolic behavior, chiral separation is increasingly important in pharmaceutical research, quality control, and regulatory submissions involving chiral drugs.

Two-Dimensional Liquid Chromatography (2D-LC)

Two-dimensional liquid chromatography integrates two chromatographic separation mechanisms within a single analytical workflow to significantly increase peak capacity and separation efficiency. This technique is particularly advantageous for complex pharmaceutical mixtures containing multiple APIs, degradation products, impurities, and excipients. Two-dimensional LC is increasingly utilized for impurity profiling, characterization of complex formulations, and comprehensive stability studies.

Green Chromatography

Green chromatography aims to minimize the environmental impact of analytical procedures by reducing solvent consumption, hazardous chemical usage, energy requirements, and analytical waste. Modern green chromatographic approaches employ eco-friendly mobile phases such as ethanol–water or methanol–water mixtures, shorter columns, lower flow rates, miniaturized systems, and UHPLC/UPLC technologies. The adoption of green analytical chemistry principles improves laboratory sustainability while maintaining analytical performance and regulatory compliance.

Table 6. Comparison of Major Chromatographic Techniques Used in Stability-Indicating Analysis

Technique	Principle	Major Advantages	Limitations	Common Applications
RP-HPLC	Separation based on hydrophobic interactions	High accuracy, robustness, wide applicability	Longer analysis time than UHPLC/UPLC	Routine assay, stability studies, simultaneous estimation
UHPLC	High-pressure separation using sub-2 µm particles	Higher resolution, faster analysis, reduced solvent consumption	Higher instrumentation cost	Stability studies, impurity profiling
UPLC	Ultra-high pressure with very small particle columns	Excellent efficiency, rapid analysis, green analytical approach	Expensive instrumentation and maintenance	Pharmaceutical quality control,

				simultaneous analysis
HPTLC	Planar chromatographic separation	Cost-effective, high sample throughput	Lower sensitivity and resolution	Herbal analysis, screening, routine quality control
LC–MS/MS	Chromatography coupled with mass spectrometry	Structural elucidation, highest sensitivity	High capital and operating cost	Degradation product identification, impurity profiling
HPLC–DAD	HPLC with diode array spectral detection	Peak purity assessment, spectral confirmation	Lower structural information than MS	Stability-indicating assays, wavelength optimization
Ion-Pair Chromatography	Separation of ionic analytes using ion-pair reagents	Improved retention of polar compounds	Method optimization can be complex	Ionic and highly polar drugs
Chiral Chromatography	Separation using chiral stationary phases	Enantiomeric purity determination	High column cost	Chiral drug analysis
Two-Dimensional LC	Sequential separation by two mechanisms	Very high peak capacity and resolution	Complex instrumentation	Complex mixtures, impurity characterization
Green Chromatography	Sustainable chromatographic approaches	Reduced solvent use, environmentally friendly	Limited applicability for some methods	Eco-friendly pharmaceutical analysis

PRINCIPLES OF STABILITY-INDICATING METHOD DEVELOPMENT

The development of a stability-indicating chromatographic method is a systematic process aimed at achieving accurate, precise, and selective separation of active pharmaceutical ingredients (APIs) from degradation products, impurities, and excipients. An ideal method should provide adequate resolution, acceptable analysis time, high sensitivity, and robustness while complying with regulatory guidelines such as ICH Q14 and ICH Q2(R2). Method development generally begins with an understanding of the physicochemical properties of the analytes, followed by optimization of chromatographic parameters to achieve the desired analytical performance.

Selection of Chromatographic Column

Column selection is one of the most critical factors affecting chromatographic separation. The stationary phase should be chosen according to the polarity, molecular size, and chemical characteristics of the analytes. Reverse-phase C18 columns are the most widely used because of their broad applicability, excellent retention, and reproducible performance. However, C8, phenyl, cyano, and polar-embedded columns may be preferred for specific applications requiring different selectivity.

Selection of Mobile Phase

The mobile phase determines the retention behavior, peak resolution, and overall chromatographic performance. It generally consists of an aqueous buffer combined with an organic solvent such as acetonitrile or methanol. Proper optimization of the mobile-phase composition is essential to obtain symmetrical peaks, adequate resolution, and acceptable run time during simultaneous analysis of combination drug products.

Selection of Organic Solvent

Organic solvents influence analyte elution, peak shape, system pressure, and analysis time. Acetonitrile is preferred because it provides low viscosity, higher elution strength, and sharper peaks, whereas methanol is commonly selected for its lower cost and better selectivity for certain compounds. In green analytical approaches, ethanol is increasingly investigated as an environmentally friendly alternative.

Selection of Buffer

Buffers are incorporated into the mobile phase to maintain a constant pH and improve chromatographic reproducibility. Commonly used buffers include phosphate, acetate, ammonium acetate, and ammonium formate buffers. Buffer selection depends on the pKa of the analytes, compatibility with the detector, and the intended chromatographic technique, particularly when coupling with mass spectrometry.

Optimization of pH

The pH of the mobile phase significantly influences analyte ionization, retention time, peak symmetry, and resolution. Proper pH optimization minimizes peak tailing and enhances chromatographic selectivity. For ionizable compounds, the mobile-phase pH is generally adjusted close to or away from the analyte's pKa to achieve optimal separation and reproducibility.

Selection of Detection Wavelength

The detection wavelength should provide maximum sensitivity while minimizing baseline interference. Ultraviolet (UV), photodiode array (PDA), or diode array detectors (DAD) are commonly employed for pharmaceutical analysis. The wavelength is typically selected based on the maximum absorbance (λmax) of the analytes obtained from UV spectral scanning.

Optimization of Flow Rate

Flow rate directly affects retention time, resolution, column efficiency, and system pressure. Lower flow rates generally improve chromatographic resolution but increase analysis time, whereas higher flow rates shorten run time at the expense of reduced separation efficiency. An optimum flow rate is selected to balance analytical performance and operational efficiency.

Selection of Injection Volume

Injection volume should be optimized to obtain adequate detector response without causing peak broadening or column overloading. Typical injection volumes range from 2–20 µL, depending on the column dimensions, detector sensitivity, and analyte concentration.

Column Temperature

Column temperature influences solvent viscosity, analyte diffusion, retention behavior, and peak shape. Maintaining a controlled temperature improves method reproducibility and reduces variations in retention time. Most pharmaceutical chromatographic methods are performed between 25°C and 40°C, although higher temperatures may be employed for difficult separations.

Optimization Strategies

Systematic optimization is essential for developing robust and reliable stability-indicating methods. Traditionally, optimization was performed using a one-factor-at-a-time (OFAT) approach; however, modern analytical development increasingly relies on Analytical Quality by Design (AQbD) and Design of Experiments (DoE) to evaluate the simultaneous

effects of multiple chromatographic variables. These strategies reduce development time, improve robustness, and ensure consistent method performance throughout the analytical lifecycle.

Common optimization parameters include:

- Selection of stationary phase
- Mobile-phase composition
- Organic solvent ratio
- Buffer type and concentration
- Mobile-phase pH
- Flow rate
- Detection wavelength
- Column temperature
- Injection volume
- Gradient program (if applicable)

Table 7. Commonly Used Chromatographic Conditions for Stability-Indicating RP-HPLC Methods

Parameter	Commonly Used Conditions
Column	C18 (150 × 4.6 mm, 5 µm) or C18 (100 × 4.6 mm, 3.5 µm)
Mobile phase	Buffer : Acetonitrile or Buffer : Methanol
Organic solvent	Acetonitrile, Methanol, Ethanol
Buffer	Phosphate, Acetate, Ammonium acetate, Ammonium formate
pH	2.5–7.0 (depending on analyte pKa)
Flow rate	0.8–1.5 mL/min
Detection wavelength	210–350 nm (drug dependent)
Injection volume	5–20 µL
Column temperature	25–40°C
Run time	5–20 min



ANALYTICAL QUALITY BY DESIGN (AQbD)

Analytical Quality by Design (AQbD) is a systematic, science- and risk-based framework for developing robust, reliable, and lifecycle-oriented analytical methods. Unlike the conventional one-factor-at-a-time (OFAT) approach, AQbD employs statistical and multivariate tools to understand the relationship between analytical variables and method performance. The implementation of ICH Q14 and ICH Q2(R2) has further encouraged the adoption of AQbD for chromatographic method development by emphasizing predefined analytical objectives, risk assessment, and continuous improvement. The AQbD workflow begins with defining the Analytical Target Profile (ATP), followed by identification of Critical Quality Attributes (CQAs) and Critical Method Parameters (CMPs) that influence chromatographic performance. Risk assessment tools such as Fishbone (Ishikawa) diagrams and Failure Mode and Effects Analysis (FMEA) are used to identify potential sources of analytical variability. Statistical optimization using Design of Experiments (DoE) and Response Surface Methodology (RSM) enables simultaneous evaluation of multiple variables, while Monte Carlo simulation predicts method robustness under varying analytical conditions. Finally, a well-defined control strategy and lifecycle management ensure that the validated method consistently meets regulatory expectations throughout routine use.

Table 8. Components of the AQbD Approach

AQbD Element	Purpose	Common Tools/Examples
Analytical Target Profile (ATP)	Defines analytical objectives and performance requirements	Assay, specificity, accuracy, precision
Critical Quality Attributes (CQAs)	Key analytical responses affecting method quality	Resolution, tailing factor, retention time
Critical Method Parameters (CMPs)	Variables influencing chromatographic performance	pH, flow rate, column, mobile phase
Risk Assessment	Identifies high-risk analytical variables	Fishbone Diagram, FMEA
Method Optimization	Determines optimum analytical conditions	DoE, Box–Behnken Design, CCD, RSM
Robustness Evaluation	Predicts analytical variability	Monte Carlo simulation
Control Strategy	Maintains consistent method performance	System suitability, SOPs
Lifecycle Management	Continuous monitoring and improvement	ICH Q14, ICH Q2(R2)

Forced Degradation Studies

Forced degradation studies are an integral part of stability-indicating method development because they provide information on the intrinsic stability of pharmaceutical substances and formulations under various stress conditions. According to ICH Q1A(R2), ICH Q1B, ICH Q2(R2), and ICH Q14, drug substances should be subjected to controlled stress conditions, including acidic, alkaline, oxidative, thermal, photolytic, and humidity exposure, to generate degradation products without causing complete decomposition of the analyte. Generally, 5–20% degradation is considered appropriate for demonstrating the specificity of a stability-indicating method. The degradation products formed during stress testing should be adequately separated from the parent drug with acceptable chromatographic resolution and peak purity. Appropriate optimization of stress conditions, including reagent concentration, exposure time, and temperature, is essential to

achieve meaningful degradation while maintaining analyte integrity. Chromatographic evaluation should include assessment of peak purity, chromatographic resolution, degradation profile, and mass balance, where the combined percentage of the remaining drug and degradation products should be close to 100%, indicating comprehensive detection of degradation pathways.

Table 9. Common Forced Degradation Conditions

Stress Condition	Typical Experimental Conditions	Objective
Acid hydrolysis	0.1–1.0 N HCl	Evaluate acid-induced degradation
Alkali hydrolysis	0.1–1.0 N NaOH	Evaluate base-induced degradation
Oxidative degradation	3–30% H_2O_2	Assess oxidation susceptibility
Thermal degradation	60–105°C	Evaluate heat stability
Humidity stress	≥75% Relative Humidity	Assess moisture-induced degradation
Photolytic degradation	UV and visible light (ICH Q1B)	Evaluate light stability

SEPARATION OF DEGRADATION PRODUCTS

The separation of degradation products is a fundamental requirement for the development of stability-indicating chromatographic methods. During stability studies, pharmaceutical compounds may degrade into structurally related impurities that can affect drug quality, safety, and efficacy. Therefore, the analytical method should accurately separate the active pharmaceutical ingredient (API) from degradation products, process-related impurities, and formulation excipients. Appropriate selection and optimization of chromatographic conditions are essential to ensure reliable identification, quantification, and regulatory compliance.

Separation Strategies

The successful separation of degradation products depends on systematic optimization of chromatographic parameters, including the stationary phase, mobile-phase composition, pH, flow rate, and elution mode. Modern chromatographic techniques such as RP-HPLC, UHPLC, UPLC, and LC–MS/MS provide high selectivity and sensitivity for separating complex mixtures. Method optimization should focus on achieving adequate peak resolution, symmetrical peak shape, acceptable retention time, and minimal interference from excipients or impurities.

Resolution and Peak Purity

Chromatographic resolution is one of the most important indicators of separation efficiency. Adequate resolution between the API and degradation products is essential to ensure accurate quantification and prevent peak overlap. In general, a resolution value of 2.0 or greater is considered acceptable for baseline separation. Peak purity analysis, commonly performed using photodiode array (PDA/DAD) or mass spectrometric detection, confirms that the analyte peak is free from co-eluting impurities or degradation products. Together, resolution and peak purity demonstrate the specificity of a stability-indicating method.

Gradient Optimization and Column Selection

Gradient elution is widely employed for the simultaneous separation of compounds with different polarities. By gradually changing the composition of the mobile phase during analysis, gradient optimization improves peak resolution, reduces analysis time, and enhances separation efficiency. Equally important is the selection of an

appropriate chromatographic column. Reverse-phase C18 columns are the most commonly used; however, C8, phenyl, cyano, and polar-embedded columns may be selected depending on the physicochemical properties of the analytes and degradation products.

Impurity Profiling

Impurity profiling involves the detection, separation, identification, and quantification of process-related impurities and degradation products present in pharmaceutical formulations. It plays a crucial role in quality control, stability evaluation, and regulatory submissions by ensuring that impurity levels remain within acceptable limits specified by ICH guidelines. Advanced analytical techniques such as LC–MS/MS and LC–HRMS are increasingly employed for structural characterization and confirmation of unknown degradation products.

Table 10. Strategies for Separation of Degradation Products

Strategy	Purpose	Outcome
Column selection	Improve chromatographic selectivity	Better resolution and peak symmetry
Mobile-phase optimization	Optimize analyte retention	Improved peak shape and reproducibility
pH optimization	Control analyte ionization	Enhanced selectivity and retention
Gradient elution	Separate compounds with different polarities	Improved resolution and shorter analysis time
Flow-rate optimization	Balance efficiency and run time	Consistent chromatographic performance
Detector selection (PDA/DAD/LC–MS)	Confirm peak identity and purity	Increased specificity and sensitivity

METHOD VALIDATION:

Method validation is a systematic process used to demonstrate that an analytical procedure is suitable for its intended purpose and consistently produces reliable, accurate, and reproducible results. Validation is an essential component of stability-indicating chromatographic methods because it ensures that the developed method can accurately quantify active pharmaceutical ingredients (APIs) in the presence of degradation products, impurities, and excipients. International regulatory agencies, including the International Council for Harmonisation (ICH Q2(R2)), the United States Pharmacopeia (USP <1225>), and the United States Food and Drug Administration (FDA), recommend comprehensive validation of analytical methods before their routine application in pharmaceutical quality control and stability studies.

Validation Parameters

A validated stability-indicating chromatographic method should demonstrate adequate specificity, selectivity, accuracy, precision, linearity, sensitivity, robustness, and reproducibility. Specificity confirms that the analyte is accurately measured without interference from impurities, degradation products, or excipients, while selectivity reflects the method's ability to distinguish closely related compounds. Accuracy is evaluated through recovery studies, whereas precision is assessed in terms of repeatability and intermediate precision under different analytical conditions. The method should also exhibit acceptable linearity over the intended

concentration range, with suitable limits of detection (LOD) and quantification (LOQ). Robustness and ruggedness ensure that minor variations in chromatographic conditions or laboratory environments do not significantly affect analytical performance.

System Suitability and Statistical Evaluation

System suitability testing is performed before routine sample analysis to verify the performance of the chromatographic system. Parameters such as retention time, theoretical plates, tailing factor, resolution, and repeatability are evaluated to ensure acceptable chromatographic performance. In addition, measurement uncertainty and statistical evaluation are increasingly recognized as important components of analytical validation. Statistical tools, including standard deviation, relative standard deviation (%RSD), confidence intervals, regression analysis, and analysis of variance (ANOVA), are commonly used to assess method reliability, precision, and overall analytical performance.

Table 11. Validation Parameters According to ICH Q2(R2), USP, and FDA

Validation Parameter	Purpose	Typical Acceptance Criteria*
Specificity	Measures analyte without interference from impurities or degradation products	No interfering peaks
Selectivity	Distinguishes analyte from closely related compounds	Complete chromatographic separation
Accuracy	Closeness of measured value to the true value	Recovery generally 98–102%
Precision	Reproducibility of analytical results	%RSD ≤ 2.0%
Repeatability	Precision under identical conditions	%RSD ≤ 2.0%
Intermediate precision	Precision across analysts, days, or instruments	%RSD within predefined limits
Linearity	Proportional response over concentration range	Correlation coefficient (R^2) ≥ 0.999
Range	Concentration interval with acceptable performance	Defined according to intended application
LOD	Lowest detectable analyte concentration	Signal-to-noise ratio ≈ 3:1
LOQ	Lowest quantifiable analyte concentration	Signal-to-noise ratio ≈ 10:1
Robustness	Resistance to small method variations	No significant change in results
Ruggedness	Reproducibility under different laboratory conditions	Consistent analytical performance
System suitability	Verifies chromatographic system performance	Meets predefined acceptance limits
Measurement uncertainty	Estimates confidence in reported results	Evaluated using statistical methods
Statistical evaluation	Confirms reliability and validity of analytical data	ANOVA, regression analysis, %RSD, confidence interval

**Acceptance limits may vary depending on the analytical procedure, regulatory guideline, and product-specific requirements.*

RECENT ADVANCES IN CHROMATOGRAPHIC METHOD DEVELOPMENT

Recent advances in chromatographic method development have significantly improved the efficiency, sensitivity, robustness, and sustainability of pharmaceutical analysis. Continuous innovations in stationary-phase technology, miniaturized analytical systems, artificial intelligence (AI), automation, and green analytical chemistry have transformed conventional chromatographic workflows into intelligent and highly efficient analytical platforms. Modern chromatographic systems not only provide faster and higher-resolution separations but also facilitate real-time monitoring, predictive optimization, and automated decision-making. These technological developments support the implementation of Analytical Quality by Design (AQbD), Process Analytical Technology (PAT), and regulatory expectations outlined in ICH Q14 and ICH Q2(R2), enabling the development of reliable and lifecycle-oriented stability-indicating analytical methods. Recent progress in AI-assisted optimization, chemometric data analysis, and sustainable chromatography is expected to further enhance pharmaceutical quality control and analytical productivity.

Advanced Chromatographic Technologies

The development of advanced stationary phases and miniaturized chromatographic systems has considerably enhanced analytical performance. Core-shell columns provide higher separation efficiency, sharper peaks, and reduced analysis time by minimizing band broadening, while monolithic columns offer excellent permeability and lower back pressure, enabling rapid analysis at higher flow rates. Emerging techniques such as nano-liquid chromatography (Nano-LC) and microfluidic chromatography require minimal sample and solvent volumes while providing high analytical sensitivity, making them particularly suitable for biomolecules and trace-level pharmaceutical analysis. These technologies improve chromatographic efficiency, reduce solvent consumption, and support the principles of green analytical chemistry.

Artificial Intelligence, Automation, and Digital Chromatography

Artificial intelligence has become an important tool in chromatographic method development by enabling intelligent optimization of experimental conditions, automated peak identification, retention time prediction, and real-time data interpretation. Machine learning (ML) algorithms analyze complex chromatographic datasets to predict optimal chromatographic conditions and improve method robustness, whereas chemometric techniques facilitate multivariate data analysis, pattern recognition, and process optimization. Integration of Process Analytical Technology (PAT) with digital chromatography enables continuous monitoring of analytical performance and supports real-time quality assurance. Furthermore, laboratory automation, robotic sample handling, and digital data management systems reduce human intervention, improve reproducibility, and increase laboratory productivity by enabling automated sample preparation, instrument operation, and analytical reporting.

Green Analytical Chemistry and Future Perspectives

Green analytical chemistry has emerged as an essential component of modern chromatographic method development by promoting environmentally sustainable analytical practices. Current approaches focus on reducing hazardous solvent consumption, minimizing energy requirements, shortening analytical run times, and utilizing environmentally friendly mobile phases such as ethanol and water-based solvent systems. Miniaturized chromatographic techniques, UHPLC systems, and solvent-efficient columns significantly reduce chemical waste while maintaining analytical performance. Continuous analytical monitoring through digital platforms, combined with AI-assisted decision-making and automated laboratory systems, represents the next generation of intelligent chromatography. These advances are expected to improve analytical sustainability, regulatory compliance, operational efficiency, and pharmaceutical quality assurance while supporting the transition toward smart, autonomous analytical laboratories.

Table 12. Recent Advances in Chromatographic Method Development

Recent Advancement	Principle	Major Advantages	Pharmaceutical Applications
Core-shell columns	Superficially porous particles	High efficiency, sharp peaks, reduced analysis time	Stability studies, impurity profiling
Monolithic columns	Continuous porous stationary phase	Low back pressure, rapid separation	High-throughput pharmaceutical analysis
Nano-LC	Miniaturized liquid chromatography	High sensitivity, low sample and solvent consumption	Bioanalysis, peptide and protein analysis
Microfluidic chromatography	Lab-on-a-chip technology	Portable, rapid, low reagent consumption	Point-of-care and pharmaceutical analysis
Artificial intelligence	Intelligent method optimization	Predictive optimization and automated decision-making	Method development and validation
Machine learning	Data-driven predictive models	Retention prediction, peak classification	AQbD and chromatographic optimization
Chemometrics	Multivariate statistical analysis	Pattern recognition and data interpretation	Method optimization and quality control
Process Analytical Technology (PAT)	Real-time analytical monitoring	Continuous process control	Pharmaceutical manufacturing
Digital chromatography	Digital data acquisition and analytics	Improved traceability and decision support	Smart analytical laboratories
Automation	Automated analytical workflow	Reduced human error and increased throughput	Routine quality control
Robotics	Automated sample handling	High reproducibility and efficiency	High-throughput screening
Green analytical chemistry	Sustainable analytical practices	Reduced solvent consumption and environmental impact	Eco-friendly pharmaceutical analysis
Continuous monitoring	Real-time process surveillance	Early detection of analytical deviations	Lifecycle management and quality assurance



Figure 1. Recent Advances in Chromatographic Method Development

REGULATORY PERSPECTIVES:

Regulatory guidelines play a pivotal role in the development, validation, and lifecycle management of stability-indicating chromatographic methods. Harmonized regulatory frameworks established by organizations such as the International Council for Harmonisation (ICH), United States Pharmacopeia (USP), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), International Organization for Standardization (ISO), and major pharmacopoeias provide standardized scientific principles for analytical method development, validation, impurity control, and pharmaceutical quality assurance. These guidelines ensure that analytical methods consistently produce accurate, precise, reliable, and reproducible results throughout the product lifecycle. Recent revisions of ICH Q2(R2) and the introduction of ICH Q14 have shifted regulatory expectations toward a science-based, risk-based, and lifecycle-oriented approach to analytical procedure development, integrating Analytical Quality by Design (AQbD) concepts and facilitating more flexible post-approval change management.

International Regulatory Guidelines

The ICH quality guidelines constitute the foundation of modern pharmaceutical analytical development. ICH Q1 provides recommendations for stability testing of new drug substances and products under long-term, intermediate, accelerated, and photostability conditions. ICH Q2(R2) establishes harmonized principles for analytical procedure validation, including specificity, accuracy, precision, linearity, robustness, detection limits, quantitation limits, and measurement uncertainty. Complementing this guideline, ICH Q14 provides a comprehensive framework for analytical procedure development by introducing Analytical Target Profiles (ATP), knowledge management, risk assessment, robustness evaluation, control strategies, and lifecycle management. In addition, ICH Q3A(R2) and ICH Q3B(R2) define regulatory requirements for identifying, qualifying, and controlling impurities in drug substances and drug products, thereby supporting impurity profiling and stability-indicating method development. These harmonized guidelines have significantly strengthened the consistency of pharmaceutical quality assessment worldwide.

Global Regulatory Agencies and Pharmacopoeias

International regulatory agencies and official pharmacopoeias provide complementary requirements for analytical procedures and pharmaceutical quality control. The USP establishes general chapters for analytical method validation, chromatographic system suitability, and verification of compendial procedures. The FDA recommends scientifically justified analytical procedure development, validation, and lifecycle management in accordance with ICH guidelines while emphasizing data integrity, risk management, and regulatory flexibility for post-approval analytical changes. The EMA adopts harmonized ICH guidance for analytical development and validation throughout the European Union. Similarly, the WHO publishes guidance for pharmaceutical quality assurance, analytical method validation, and stability studies that supports global medicine quality, particularly in resource-limited settings. The ISO quality management standards, especially ISO 17025 and ISO 9001, contribute to laboratory competence, quality management systems, traceability, and continual improvement. In addition, official pharmacopoeias such as the European Pharmacopoeia (Ph. Eur.), British Pharmacopoeia (BP), Japanese Pharmacopoeia (JP), and Indian Pharmacopoeia (IP) provide harmonized monographs, chromatographic procedures, acceptance criteria, and quality specifications for pharmaceutical products.

Recent Regulatory Updates

Recent regulatory developments have transformed analytical method development from a validation-focused approach to a comprehensive lifecycle management strategy. The adoption of ICH Q2(R2) and ICH Q14 introduces enhanced concepts such as Analytical Target Profiles, risk-based analytical development, multivariate experimental design, control strategies, robustness evaluation, and science-based management of post-approval analytical changes. These updates also recognize advanced analytical technologies, multivariate analytical procedures, and real-time analytical approaches while strengthening the integration of AQbD principles into regulatory submissions. Consequently, modern regulatory expectations encourage continuous improvement, analytical flexibility, digitalization, and lifecycle management to ensure consistent pharmaceutical quality and regulatory compliance.

Table 13. Major Regulatory Guidelines for Chromatographic Method Development

Guideline	Scope	Major Regulatory Focus
ICH Q1 Series	Stability testing	Long-term, accelerated, intermediate and photostability studies
ICH Q2(R2)	Analytical method validation	Validation characteristics, measurement uncertainty, lifecycle validation
ICH Q3A(R2)	Impurities in drug substances	Identification, qualification and reporting of impurities
ICH Q3B(R2)	Impurities in drug products	Control of degradation products and formulation impurities
ICH Q14	Analytical procedure development	AQbD, ATP, risk assessment, control strategy and lifecycle management
USP <1225>	Validation of compendial procedures	Analytical validation and system suitability
FDA Guidance	Pharmaceutical analytical procedures	Validation, data integrity and regulatory flexibility

EMA Guidance	Analytical development	Harmonized implementation of ICH quality guidelines
WHO Guidelines	Pharmaceutical quality assurance	Analytical methods, stability studies and quality control
ISO Standards	Laboratory quality systems	Laboratory competence, traceability and quality management

CONCLUSION

Stability-indicating chromatographic methods have become indispensable for ensuring the quality, safety, efficacy, and regulatory compliance of modern pharmaceutical products, particularly fixed-dose combination formulations. Advances in chromatographic instrumentation, stationary-phase technology, and analytical software have significantly enhanced the sensitivity, selectivity, and robustness of simultaneous drug estimation while enabling efficient separation of degradation products and impurities. The implementation of Analytical Quality by Design (AQbD) has transformed analytical method development from an empirical trial-and-error process into a systematic, science- and risk-based approach supported by statistical optimization, knowledge management, and lifecycle monitoring. Furthermore, recent regulatory developments, particularly ICH Q14 and ICH Q2(R2), have reinforced the importance of analytical procedure development, comprehensive validation, measurement uncertainty, and continuous performance verification throughout the analytical lifecycle.

Emerging technologies, including core-shell and monolithic columns, nano-liquid chromatography, microfluidic systems, artificial intelligence, machine learning, chemometrics, digital chromatography, process analytical technology (PAT), laboratory automation, robotics, and green analytical chemistry, are reshaping pharmaceutical analysis by improving analytical efficiency, reducing environmental impact, and enabling real-time quality assurance. Future research is expected to focus on intelligent and autonomous chromatographic systems that integrate predictive analytics, digital laboratory platforms, and sustainable analytical practices. Such innovations will further strengthen pharmaceutical quality control, facilitate regulatory flexibility, and support continuous manufacturing initiatives. Overall, stability-indicating chromatographic methods will remain central to pharmaceutical research, quality assurance, and regulatory science, providing reliable analytical solutions for the development, evaluation, and lifecycle management of increasingly complex combination drug products.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest.

REFERENCES

1. Bakshi M, Singh S. Development of validated stability-indicating assay methods—critical review. J Pharm Biomed Anal. 2002;28(6):1011–40.
2. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs—a review. J Pharm Anal. 2014;4(3):159–65.
3. Singh S, Bakshi M. Guidance on conduct of stress tests to determine inherent stability of drugs. Pharm Technol. 2000;24(2):1–14.
4. Singh S, Junwal M, Modhe G, Tiwari H, Kurmi M, Parashar N, et al. Forced degradation studies to assess the stability of

drugs and products. Trends Anal Chem. 2013;49:71–88.
5. Reynolds DW, Facchine KL, Mullaney JF, Alsante KM, Hatajik TD, Motto MG. Conducting forced degradation studies. Pharm Technol. 2002;26(2):48–56.
6. Alsante KM, Ando A, Brown R, Ensing J, Hatajik TD, Kong W, et al. The role of degradant profiling in active pharmaceutical ingredients and drug products. Adv Drug Deliv Rev. 2007;59(1):29–37.
7. Baertschi SW, Alsante KM, Reed RA, editors. Pharmaceutical Stress Testing: Predicting Drug Degradation. 2nd ed. New York: Informa Healthcare; 2011.
8. Carstensen JT, Rhodes CT. Drug Stability: Principles and Practices. 3rd ed. New York: Marcel Dekker; 2000.
9. Ahuja S, Scypinski S. Handbook of Modern Pharmaceutical Analysis. London: Academic Press; 2001.
10. Ahuja S, Rasmussen H. HPLC Method Development for Pharmaceuticals. Amsterdam: Elsevier; 2007.
11. Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. 3rd ed. Hoboken: John Wiley & Sons; 2010.
12. Dong MW. Modern HPLC for Practicing Scientists. 2nd ed. Hoboken: John Wiley & Sons; 2019.
13. Swartz ME, Krull IS. Analytical Method Development and Validation. New York: Marcel Dekker; 2012.
14. Kazakevich Y, Lobrutto R. HPLC for Pharmaceutical Scientists. Hoboken: John Wiley & Sons; 2007.
15. Meyer VR. Practical High-Performance Liquid Chromatography. 5th ed. Chichester: Wiley; 2010.
16. Ermer J, Miller JHM, editors. Method Validation in Pharmaceutical Analysis: A Guide to Best Practice. 2nd ed. Weinheim: Wiley-VCH; 2014.
17. Rozet E, Hubert C, Ceccato A, Dewé W, Ziemons E, Moonen F, et al. Using design space for analytical methods. Trends Anal Chem. 2013;42:157–67.
18. Monks K, Molnár I, Rieger HJ, Bogáti B, Szabó E. Quality by Design: multidimensional exploration of the design space in high-performance liquid chromatography method development. J Chromatogr A. 2012;1232:218–30.
19. Debrus B, Lebrun P, Kindenge JM, Lecomte F, Ceccato A, Caliaro G, et al. Innovative high-performance liquid chromatographic method development for pharmaceutical analysis using AQbD principles. J Pharm Biomed Anal. 2011;54(2):181–8.
20. Reid GL, Morgado J, Barnett K, Harrington B, Wang J, Harwood JW, et al. Analytical Quality by Design (AQbD) in pharmaceutical analysis. Pharm Technol. 2013;37(6):52–9.
21. Orlandini S, Pinzauti S, Furlanetto S. Analytical Quality by Design in chromatographic method development. Anal Bioanal Chem. 2013;405(2–3):443–50.
22. Furlanetto S, Orlandini S, Pinzauti S. Design of Experiments in pharmaceutical analytical method development. Anal Bioanal Chem. 2013;405:451–64.
23. Rozet E, Marini RD, Ziemons E, Boulanger B, Hubert P. Advances in analytical method validation using Quality by Design. Trends Anal Chem. 2011;30(7):1058–72.
24. Chew YL, Khor MA, Lim YY. Choices of chromatographic methods as stability indicating assays for pharmaceutical products: a review. Heliyon. 2021;7(3):e06553.
25. Abreu JC, Mahr AG, do Lago CL, et al. Stability-indicating method development for quantification of bromopride, its impurities, and degradation products by ultra-high

performance liquid chromatography applying Analytical Quality by Design principles. J Pharm Biomed Anal. 2021;205:114306.
26. International Council for Harmonisation (ICH). ICH Q1A(R2): Stability Testing of New Drug Substances and Products. Geneva: ICH; 2003.
27. International Council for Harmonisation (ICH). ICH Q2(R2): Validation of Analytical Procedures. Geneva: ICH; 2023.
28. International Council for Harmonisation (ICH). ICH Q3A(R2): Impurities in New Drug Substances. Geneva: ICH; 2006.
29. International Council for Harmonisation (ICH). ICH Q3B(R2): Impurities in New Drug Products. Geneva: ICH; 2006.
30. International Council for Harmonisation (ICH). ICH Q14: Analytical Procedure Development. Geneva: ICH; 2023.
31. Dong MW. Recent advances in high-performance liquid chromatography for pharmaceutical analysis. J Pharm Biomed Anal. 2019;177:112856.
32. Deidda R, Orlandini S, Hubert P, Hubert C. Risk-based approach for method development in pharmaceutical quality control: A critical review. J Pharm Biomed Anal. 2018;161:110–121.
33. Tome T, Žigart N, Časar Z, Obreza A. Development and optimization of liquid chromatographic analytical methods by using Analytical Quality by Design principles: Overview and recent advances. Org Process Res Dev. 2019;23(9):1784–1802.
34. Bastogne T, et al. A state-of-the-art review of Analytical Quality by Design for pharmaceutical analysis. J Pharm Biomed Anal. 2022;219:114890.
35. Yabre M, et al. Development of a green HPLC method for the analysis of artesunate and amodiaquine impurities using Quality by Design. J Pharm Biomed Anal. 2020;186:113318.
36. Ntontis S, et al. Analytical Quality by Design approach for determination of imidazole impurities using HILIC chromatography. J Pharm Biomed Anal. 2023;223:115138.
37. Lopes IDJN, et al. Application of AQbD for stability-indicating method development for quantification of nevirapine and degradation products. J Chromatogr B. 2019;1124:252–261.
38. Kochling J, Wu W, Hua Y, Guan Q, Castaneda-Merced J. A platform AQbD approach for UHPLC-UV and UHPLC-MS method development for protein analysis. J Pharm Biomed Anal. 2016;125:130–139.
39. Rozet E, Hubert P, Ziemons E, et al. Total error concept and uncertainty approach in analytical method validation. J Chromatogr A. 2007;1158(1–2):126–137.
40. Hubert P, Nguyen-Huu JJ, Boulanger B, et al. Harmonization of strategy for analytical validation. J Pharm Biomed Anal. 2007;45(1):70–81.
41. Chew YL, Khor MA, Lim YY. Choices of chromatographic methods as stability-indicating assays for pharmaceutical products: A review. Heliyon. 2021;7(3):e06553.
42. Ramisetti NR, Kuntamukkala R. LC-MS/MS characterization of forced degradation products of ambrisentan and development of a stability-indicating RP-HPLC method. New J Chem. 2014;38:3050–3061.
43. Rao BM, Chakraborty A, Srinivasu M, et al. A stability-indicating HPLC assay method for docetaxel. J Pharm Biomed Anal. 2006;41(3):676–681.
44. Ravisankar P, Swathi V, Srinivasa BP, Sultana GS. Current trends in forced degradation studies and stability-indicating analytical methods. IOSR J Pharm Biol Sci. 2017;12(5):17–36.

45. Al Azzam KM, Saad B, Tat CY, et al. Stability-indicating micellar electrokinetic chromatography method for sumatriptan succinate. J Pharm Biomed Anal. 2011;56(5):937–943.
46. Thoppil SO, Cardoza RM, Amin P. Stability-indicating HPTLC determination of trimetazidine in pharmaceutical formulations. J Pharm Biomed Anal. 2001;25(1):15–20.
47. ICH. Q8(R2): Pharmaceutical Development. Geneva: International Council for Harmonisation; 2009.
48. ICH. Q9(R1): Quality Risk Management. Geneva: International Council for Harmonisation; 2023.
49. ICH. Q10: Pharmaceutical Quality System. Geneva: International Council for Harmonisation; 2008.
50. United States Pharmacopeia. USP General Chapter <1225> Validation of Compendial Procedures. Rockville (MD): United States Pharmacopeial Convention; Latest edition.
51. United States Pharmacopeia. USP General Chapter <621> Chromatography. Rockville (MD): United States Pharmacopeial Convention; Latest edition.
52. US Food and Drug Administration. Analytical Procedures and Methods Validation for Drugs and Biologics: Guidance for Industry. Silver Spring (MD): FDA; 2015.
53. European Medicines Agency. ICH Q2(R2): Validation of Analytical Procedures—Scientific Guideline. Amsterdam: EMA; 2024.
54. World Health Organization. WHO Technical Report Series No. 1010: Annex—Guidelines on Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products. Geneva: WHO; 2018.
55. International Organization for Standardization. ISO/IEC 17025:2017—General Requirements for the Competence of Testing and Calibration Laboratories. Geneva: ISO; 2017.
56. Jawarkar SG, Amliyar G, Khan N, et al. Identification and characterization of trametinib degradation product employing Orbitrap LC-HRMS and development of a robust eco-friendly stability-indicating analytical method. J Pharm Biomed Anal. 2026;272:117355.
57. Enhancing pharmaceutical analysis with Analytical Quality by Design in UHPLC: A review of methodological innovations (2014–2025). Crit Rev Anal Chem. 2025.
58. Bellaaj E, Elleuch A, Louati K. Validation of an HPLC-UV method for apixaban stability-indicating study. Biomed Chromatogr. 2026;40(7):e70496.
59. Patil P, et al. Analytical Quality by Design-based reverse-phase HPLC method development for biomarkers: A comprehensive review of quality assessment and analytical trends. Biomed Chromatogr. 2026.
60. Doan TX, Nguyen HMT, Hoang VD. Recent applications of Analytical Quality-by-Design methodology for chromatographic analysis: A review. Trends Anal Chem. 2024.
61. Desmet G, Eeltink S. Well-defined materials for high-performance chromatographic separation. Annu Rev Anal Chem. 2019;12:181–214.
62. Parys W, Dołowy M, Pyka-Pająk A. Significance of chromatographic techniques in pharmaceutical analysis. Pharmaceuticals (Basel). 2022;15:172.
63. Patel N, Gupta KR, Umekar MJ. An overview of monolithic columns: Types, parameters and applications. J Drug Deliv Ther. 2022;12(1):223–231.
64. Perchepied S, Ritchie H, Desmet G, Eeltink S. Insights into column packing processes of narrow-bore and capillary-scale columns: A

tutorial review. Anal Chim Acta. 2022;1235:340563.
65. Pinto EC, Gonçalves MD, Cabral LM, Armstrong DW, de Sousa VP. Development and validation of a stability-indicating HPLC method using a mixed-mode column and charged aerosol detector. J Sep Sci. 2018;41(8):1716–1725.
66. Elagamy SH. Emerging trends and advancements in HPLC technique: The role of nanotechnology, machine learning, and AI optimization. Biomed Chromatogr. 2026;40(8):e70535.
67. Meher AK, Zarouri A. Green analytical chemistry—Recent innovations. Analytica. 2025;6(1):10.
68. Mehta M, Mehta D, Mashru R. Recent application of green analytical chemistry: Eco-friendly approaches for pharmaceutical analysis. Future J Pharm Sci. 2024;10:83.
69. Patil SD, Karode SR, Kolate NR, Korde TM. Recent approaches in green liquid chromatography for pharmaceutical analysis: A comprehensive review on green analytical sustainable chemistry. Sustain Chem One World. 2025;6:100069.
70. Mehta A, Sharma A, Sharma N, Tyagi LK, Sethi VA. Recent advances and applications of green analytical chemistry in environmental monitoring, food safety, and pharmaceutical analysis. Curr Green Chem. 2026;13(2):125–147.
71. Elagamy SH, Chanduluru HK, Obaydo RH, Lotfy HM. The role of artificial intelligence in modern analytical chemistry: Current trends and future directions. Int J Anal Chem. 2026;2026:2645726.
72. Orlandini S, Furlanetto S. Chemometric tools in chromatographic method development and optimization. Anal Bioanal Chem. 2013;405:443–450.
73. Brereton RG. Chemometrics for Pattern Recognition. Chichester: Wiley; 2009.
74. Otto M. Chemometrics: Statistics and Computer Application in Analytical Chemistry. 3rd ed. Weinheim: Wiley-VCH; 2016.
75. Wold S, Sjöström M, Eriksson L. PLS-regression: A basic tool of chemometrics. Chemom Intell Lab Syst. 2001;58:109–130.
76. Bakeev KA, editor. Process Analytical Technology: Spectroscopic Tools and Implementation Strategies for the Chemical and Pharmaceutical Industries. 2nd ed. Oxford: Wiley-Blackwell; 2010.
77. Simon LL, Pataki H, Marosi G, et al. Assessment of recent process analytical technology (PAT) trends. Org Process Res Dev. 2015;19:3–62.
78. Rathore AS, Bhambure R, Ghare V. Process analytical technology (PAT) for pharmaceutical manufacturing. Anal Bioanal Chem. 2010;398:137–154.
79. Roggo Y, Chalus P, Maurer L, et al. A review of near infrared spectroscopy and chemometrics in pharmaceutical technologies. J Pharm Biomed Anal. 2007;44:683–700.
80. Bakeev KA. PAT and continuous pharmaceutical manufacturing: Current status and future directions. J Pharm Innov. 2019;14:1–12.
81. Eeltink S, Desmet G. Advances in capillary and nano-liquid chromatography for pharmaceutical and bioanalytical applications. LC GC North Am. 2018;36:20–29.
82. Abonamah JV, Eckenrode BA, Moini M. On-site detection of fentanyl derivatives using nano-liquid chromatography–electron ionization–mass spectrometry. Forensic Chem. 2019;16:100180.

83. Svec F. Monolithic columns: A historical overview and future perspectives. J Sep Sci. 2017;40:4–18.
84. Gritti F, Guiochon G. Mass transfer kinetics in modern core-shell particles. J Chromatogr A. 2012;1221:2–40.
85. Neue UD. Theory of peak capacity in modern liquid chromatography. J Chromatogr A. 2005;1079:153–161.
86. Snyder LR, Dolan JW. High-performance gradient elution: The practical application of the linear-solvent-strength model. J Chromatogr A. 2007;1158:115–127.
87. Guillarme D, Fekete S, Veuthey JL. Modern UHPLC technologies in pharmaceutical analysis. TrAC Trends Anal Chem. 2014;63:2–14.
88. Fekete S, Veuthey JL, Guillarme D. New trends in UHPLC for pharmaceutical analysis. Anal Bioanal Chem. 2015;407:5–14.
89. Swartz ME. UPLC™: An introduction and review. J Liq Chromatogr Relat Technol. 2005;28:1253–1263.
90. Dolan JW. Peak resolution and selectivity optimization in reversed-phase liquid chromatography. LC GC North Am. 2016;34:742–751.
91. Patel JK, Patel J. Stability indicating RP-HPLC method by QbD approach and LC-MS characterization of degradation products of mifepristone. J Chromatogr Sci. 2025;63(4):bmaf017.
92. Yassin MG, Roshdy A, Marie AA. Stability indicating RP-HPLC technique for simultaneous estimation of nirmatrelvir and ritonavir in their new copackaged dosage form for COVID-19 treatment. Sci Rep. 2025;15:2281.
93. Mamidi SVS, Atmakuri LR, Mamidipalli WC. Stability-indicating high-performance liquid chromatographic method for simultaneous assay of pibrentasvir and glecaprevir: method development, validation and application to tablet dosage forms. J Res Pharm. 2025;23(3):1–15.
94. Panchumarthy R. A stability-indicating RP-HPLC method for determination of foslevodopa and foscarbidopa in bulk and formulation. Sep Sci Plus. 2025.
95. Pippalla S, Chintala V. Stability-indicating RP-HPLC method development and validation for determination of impurities in loperamide hydrochloride capsule dosage form. Biomed Chromatogr. 2025.
96. Tiwari AR, Ambadekar SR, Bagul VA. Sensitive and sustainable stability-indicating RP-HPLC method for simultaneous assay and impurity profiling of amitriptyline hydrochloride: green metric, RGB model and forced degradation study. Discover Chemistry. 2025;2:157.
97. Ponnekanti K, Godela R, Solipeta DR, Sujatha K, Beda DP, et al. A novel RP-HPLC stability-indicating method for simultaneous estimation of niraparib and abiraterone in synthetic mixtures and combined tablet formulations. Discover Applied Sciences. 2025;7:499.
98. Ibrahim M, Irfan M, Khalid SH. Validated isocratic stability-indicating RP-HPLC method for concurrent remdesivir estimation in drug products used in bioavailability studies. Pak J Pharm Sci. 2025;38(6):2120–2128.
99. Patel N, Pandya M, Rawat F, Goswami J, Prajapati D, Thummar KN, et al. Novel stability-indicating RP-HPLC method for remdesivir with LC-MS/MS identification of degradation products. Discover Chemistry. 2025;2:351.
100. Bankar AR, Chaurasia S, Singh I. Advanced stability-indicating RP-HPLC method for the quantification of lurasidone hydrochloride in bulk and PLGA-based in situ implant

formulation. Ann Pharm Fr. 2025;83(2):342–357.
101. O'Neill R, Yoo O, Burcham P, Nguyen M, Lim LY. Development and validation of a stability-indicating RP-HPLC method for edaravone quantification. Molecules. 2025;30(13):2866.
102. Guillarme D, Fekete S, Veuthey JL. Recent advances in UHPLC for pharmaceutical analysis. TrAC Trends Anal Chem. 2014;63:2–14.
103. Fekete S, Veuthey JL, Guillarme D. Modern UHPLC strategies in pharmaceutical analysis. Anal Bioanal Chem. 2015;407:5–14.
104. Desmet G, Eeltink S. High-efficiency chromatographic separations using advanced stationary phases. Annu Rev Anal Chem. 2019;12:181–214.
105. Svec F. Monolithic columns: Recent developments and pharmaceutical applications. J Sep Sci. 2017;40:4–18.
106. Gritti F, Guiochon G. Core-shell particles in liquid chromatography: Fundamentals and applications. J Chromatogr A. 2012;1221:2–40.
107. Simon LL, Pataki H, Marosi G, et al. Assessment of recent process analytical technology (PAT) trends. Org Process Res Dev. 2015;19:3–62.
108. Rathore AS, Bhambure R, Ghare V. Process analytical technology in pharmaceutical manufacturing. Anal Bioanal Chem. 2010;398:137–154.
109. Roggo Y, Chalus P, Maurer L, et al. A review of near-infrared spectroscopy and chemometrics in pharmaceutical technologies. J Pharm Biomed Anal. 2007;44:683–700.
110. Wold S, Sjöström M, Eriksson L. PLS-regression: A basic tool of chemometrics. Chemom Intell Lab Syst. 2001;58:109–130.
111. Otto M. Chemometrics: Statistics and Computer Application in Analytical Chemistry. 3rd ed. Weinheim: Wiley-VCH; 2016.
112. Brereton RG. Chemometrics for Pattern Recognition. Chichester: Wiley; 2009.
113. Elagamy SH, Chanduluru HK, Obaydo RH, Lotfy HM. The role of artificial intelligence in modern analytical chemistry: Current trends and future directions. Int J Anal Chem. 2026;2026:2645726.
114. Meher AK, Zarouri A. Green analytical chemistry: Current innovations and future perspectives. Analytica. 2025;6:10.
115. Mehta M, Mehta D, Mashru R. Green analytical chemistry in pharmaceutical analysis: Recent advances. Future J Pharm Sci. 2024;10:83.
116. Patil SD, Karode SR, Kolate NR, Korde TM. Green liquid chromatography for pharmaceutical analysis: A comprehensive review. Sustain Chem One World. 2025;6:100069.
117. Elagamy SH. Emerging trends and advancements in HPLC: Nanotechnology, machine learning and AI optimization. Biomed Chromatogr. 2026;40:e70535.
118. Doan TX, Nguyen HMT, Hoang VD. Recent applications of Analytical Quality-by-Design methodology for chromatographic analysis. TrAC Trends Anal Chem. 2024.
119. Bellaaj E, Elleuch A, Louati K. Validation of an HPLC-UV stability-indicating method for apixaban. Biomed Chromatogr. 2026;40:e70496.
120. Jawarkar SG, Amliyar G, Khan N, et al. Identification and characterization of trametinib degradation products employing Orbitrap LC-HRMS and development of a robust eco-friendly stability-indicating analytical method. J Pharm Biomed Anal. 2026;272:117355.

HOW TO CITE: Ajinkya Gulhane, Dr. Neelima Naneriya, Recent Advances in Stability-Indicating Chromatographic Methods for Simultaneous Quantitative Analysis of Combination Drug Products: Principles, Method Development Strategies, Validation, And Regulatory Perspectives, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 8, 736-763, https://doi.org/10.5281/zenodo.21802665